ChromaDex announces an exclusive worldwide patent license and research agreement with The Scripps Research Institute to identify the potential role of NIAGEN ® in treating breast cancer

ChromaDex announces an exclusive worldwide patent license and

research agreement with The Scripps Research Institute to identify

the potential role of NIAGEN in treating

IRVINE, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- ChromaDex

Corp. (NASDAQ: CDXC), an

innovator of proprietary health, wellness and nutritional

ingredients that creates science-based solutions for dietary

supplement, food and beverage, skin care, sports nutrition, and

pharmaceutical products announced today that it has signed a new,

exclusive patent license and research agreement with The Scripps

Research Institute (TSRI), gaining access to groundbreaking,

pre-clinical discoveries by Dr. Brunie Felding.

Felding's patented discoveries include the enhancement of

NAD+ metabolism through treatment with NAD+ precursors to

potentiate the effects of endocrine therapy in breast cancer,

inhibit resistance of breast cancer cells to endocrine therapy, and

re-instate sensitivity in breast cancer cells that are unresponsive

to endocrine treatments such as Tamoxifen. The research agreement

will build upon the previous material

transfer agreement, and if successful, will yield the data

and tools required for the development of a clinical trial

evaluating a novel combination therapy consisting of nicotinamide

riboside (NR) and endocrine therapy in the treatment of breast

acquisition brings the total number of patents and patents pending

relating to nicotinamide riboside, owned or exclusively licensed by

Founder and CEO, Frank Jaksch, stated, TSRI was one of the

first institutions we signed a material transfer agreement with on

NR back in 2013. It's great to see that TSRI's

discoveries have now sparked a collaborative partnership that could

lead to another drug application.

Scientific Affairs Director, Amy Boileau commented, Though

the research is still early stage, the findings by Dr. Felding and

her team are remarkable. We are thrilled to expand our partnership

with TSRI and continue advancing research that holds great promise

for improved treatment of breast cancer.

TSRI team is equally pleased to build upon the existing

partnership. Our research indicates that normalizing tumor

cell metabolism could very efficiently enhance cancer

therapy, said Dr. Felding. The planned studies may

identify a novel way to enhance treatment responses and improve the

quality of life for cancer patients.

new research program adds to a robust, existing lineup of over 100

collaborative research studies with leading universities and

research institutions, representing an estimated $50 million in NR

research. Being publicly traded on NASDAQ, ChromaDex gives the

public an opportunity to invest in the business of science-based

technologies that promote healthy aging and longevity. For more

information on ChromaDex, visit www.chromadex.com.

ChromaDex leverages its complementary business units to discover,

acquire, develop and commercialize patented and proprietary

ingredient technologies that address the dietary supplement, food,

beverage, skin care and pharmaceutical markets. In addition to our

ingredient technologies unit, we also have business units focused

on natural product fine chemicals (known as "phytochemicals"),

chemistry and analytical testing services, and product regulatory

and safety consulting. As a result of our relationships with

leading universities and research institutions, we are able to

discover and license early stage, IP-backed ingredient

technologies. We then utilize our in-house chemistry, regulatory

and safety consulting business units to develop commercially viable

ingredients. ChromaDex's current proprietary ingredient

portfolio is backed with clinical and scientific research, as well

as extensive IP protection. In addition to

NIAGEN nicotinamide riboside;

pTeroPure pterostilbene;

PURENERGY , a caffeine-pTeroPure co-crystal;

IMMULINA , a spirulina extract; and

AnthOrigin , anthocyanins derived from a

domestically-produced, water-extracted purple corn

Forward-Looking Statements:

This release contains forward-looking statements within the meaning

of Section 27A of the Securities Act of 1933, as amended, and

Section 21E of the Securities and Exchange Act of 1934, as

amended, including statements related to the discoveries and

research by Dr. Felding, the potential role of

NIAGEN in treating breast

cancer, the potential for future clinical trials and drug

applications, whether normalizing cell metabolism may enhance

cancer therapy, and the results of the NIAGEN studies

and their significance. Statements that are not a description of

historical facts constitute forward-looking statements and may

often, but not always, be identified by the use of such words as

"expects", "anticipates", "intends", "estimates", "plans",

"potential", "possible", "probable", "believes", "seeks", "may",

"will", "should", "could" or the negative of such terms or other

similar expressions. More detailed information about ChromaDex and

the risk factors that may affect the realization of forward-looking

statements is set forth in ChromaDex's Annual Report on Form 10-K

for the fiscal year ended December 31, 2016, ChromaDex's Quarterly

Reports on Form 10-Q and other filings submitted by ChromaDex to

the SEC, copies of which may be obtained from the SEC's website at

Readers are cautioned not to place undue reliance on these

forward-looking statements, which speak only as of the date hereof,

and actual results may differ materially from those suggested by

these forward-looking statements. All forward-looking statements

are qualified in their entirety by this cautionary statement and

ChromaDex undertakes no obligation to revise or update this release

to reflect events or circumstances after the date

ChromaDex Public Relations Contact:

Ostendorf, Director of Marketing